RALEIGH, N.C., May 03, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today issued the following statement with respect to its receipt of a notice from Broadfin Capital, LLC (together with its affiliates, “Broadfin”) of nominations of director candidates for election to BDSI’s Board of Directors at the 2018 annual meeting of shareholders (the “2018 Annual Meeting”):

BDSI has always been committed to maintaining a constructive dialogue with all of its shareholders, including Broadfin. Consistent with this commitment, BDSI has recently engaged in an ongoing dialogue with Broadfin regarding a wide array of matters, and intends to continue this dialogue with the goal of enhancing value for all BDSI shareholders.

BDSI will present its recommendation with respect to the election of directors in its proxy statement to be filed with the Securities and Exchange Commission (the “SEC”). The 2018 Annual Meeting has not yet been scheduled and shareholders of BDSI need not take any action at this time.

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA^®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.